

CORDLIFE GROUP LIMITED
(Company Registration No.: 200102883E)
(Incorporated in the Republic of Singapore)

RECEIPT OF NOTICE FROM THE MINISTRY OF HEALTH

The Board of Directors (the "**Board**") of Cordlife Group Limited (the "**Company**" and together with its subsidiaries, the "**Group**") wishes to inform that the Company has on 30 November 2023 received a notice from the Ministry of Health ("**MOH**") to stop, for a period up to six months, the collection, testing, processing and/or storage any new cord blood and human tissues, or provide any new types of tests to patients, pending the Company's written representations to MOH (the "**Notice**").

The Company together with MOH had detected that seven of its cryogenic storage tanks based in Singapore have been exposed to temperatures outside of their normal temperature range from November 2020 to date. Since the detection of these irregularities, the Company has undertaken viability testing of donated cord blood samples stored within one of the affected tanks, which represents approximately 2.66% of cord blood units stored by the Company. MOH separately appointed a panel of cord blood banking experts who have determined that the cord blood units in this affected tank are unlikely to be suitable for stem cell transplant purposes. The Company will however still continue to store these cord blood units for its clients, as they may be valuable in light of developments in the field of cell and gene therapy.

MOH conducted several audits on the Company in August and November 2023 and the Company has been cooperating fully with such audits, including all requests for clarifications and explanations. For the other six tanks where irregular temperature readings were detected, investigations with MOH are still ongoing and the Company will continue to cooperate fully with such investigations. As a further measure of quality control, the Company will voluntarily initiate viability testing of donated cord blood samples stored in all other unaffected tanks.

The Company is in the process of contacting all clients that have stored cord blood in its Singapore facility, to inform them of the status of their cord blood units or to outline the ongoing testing.

Under the Company's standard service agreement with all clients, if, in the opinion of their healthcare provider, it is subsequently determined that the cord blood cannot be successfully used for an approved cord blood transplant, the Company will make every effort to find a suitable replacement cord blood for their child.

MOH has also notified the Company that it has found certain process lapses relating to the temperature monitoring system, maintenance of certain tanks and the validation of a new cord blood processing method.

As stated in the Notice, the Company has 14 days to make representations to MOH in relation to the contents of the Notice. The Company is presently seeking advice on the appropriate response to the Notice and will provide an update in due course.

Following these incidents, the Company has conducted a thorough investigation into how the irregularities had occurred and has reinforced its internal processes to prevent similar occurrences in the future. The Company will continue working closely with MOH to strengthen its laboratory processes, procedures and staff training.

Due to the uncertainty of the outcome of ongoing investigations, the Company is unable to assess the financial impact on the financial performance of the Group for the financial year ending 31 December 2023. In the meantime, shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company. They should consult their stockbrokers, bank managers, solicitors, or other professional advisers if they have any doubt about the actions they should take.

The Company will update its shareholders and the investing public, if there are any material developments in relation to the above, in accordance with the requirements of the SGX-ST listing rules.

For and on behalf of the Board
CORDLIFE GROUP LIMITED

Tan Poh Lan
Executive Director and Group CEO

30 November 2023